<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="drugs for safety and efficacy enables clinicians to make evidence-based" exact="treatment" post="decisions and contributes to overall outbreak control. However, it"/>
 <result pre="clinical data (including clinical trial, observational and case series) describing" exact="treatment" post="for patients with influenza A(H1N1)pdm09 and ClinicalTrials.gov for research"/>
 <result pre="patients with the disease. Results Thirty-three thousand eight hundred sixty-nine" exact="treatment" post="courses for patients hospitalised with A(H1N1)pdm09 were detailed in"/>
 <result pre="observational studies or case series. Five hundred ninety-two patients received" exact="treatment" post="(or placebo) as participants in a registered interventional clinical"/>
 <result pre="COVID-19. One important element of pandemic mitigation is prophylaxis and" exact="treatment" post="of patients. For emerging viral infections, antiviral therapies are"/>
 <result pre="important, because it represents what is available to clinicians making" exact="treatment" post="decisions for patients under conditions of significant uncertainty [3],"/>
 <result pre="includes registered trials which were not completed, and reports of" exact="treatment" post="outside a formal trial setting (case studies or series"/>
 <result pre="this to the outbreak epidemiology Research can only influence patient" exact="treatment" post="in the current outbreak by providing enhanced evidence if"/>
 <result pre="report key clinical parameters, including those needed for stratification of" exact="treatment" post="effect (the age of patients, the pregnancy status of"/>
 <result pre="status of patients) or indicate the quality of reporting of" exact="treatment" post="effect (adverse events due to treatment) We have selected"/>
 <result pre="would be necessary to know in order to evaluate a" exact="treatment" post="effect. Describe the outcomes of clinical research that was"/>
 <result pre="appendix 2. To capture information on how many patients received" exact="treatment" post="outside of a trial, we included case studies, case"/>
 <result pre="with seasonal reporting). We excluded papers if the description of" exact="treatment" post="was not quantifiable or the treatment name was absent"/>
 <result pre="if the description of treatment was not quantifiable or the" exact="treatment" post="name was absent (including use of the general term"/>
 <result pre="(including use of the general term â€˜antiviral therapyâ€™). We defined" exact="treatment" post="as pathogen-directed therapy (e.g. antivirals) or host-directed therapy where"/>
 <result pre="4) that describe 39,577 hospitalised patients with A(H1N1)pdm09 and 33,869" exact="treatment" post="courses (TableÂ 2). Twelve different treatments were used, with"/>
 <result pre="of patients). Fig. 1 Study selection Table 2 Volume of" exact="treatment" post="courses described in the literature for hospitalised patients Treatment"/>
 <result pre="of patients receiving treatment1 Median (IQR) number of patients receiving" exact="treatment" post="per publication2 FDA drug approval status for use in"/>
 <result pre="Statins3 1 12 12 Not approved for influenza Volume of" exact="treatment" post="courses described in the literature for hospitalised patients with"/>
 <result pre="EUA emergency use authorization 1Some patients received more than one" exact="treatment" post="2When publication describes use of that drug 3Where clear"/>
 <result pre="to the type of the study and the number of" exact="treatment" post="courses described. The pandemic period ranges from the 1st"/>
 <result pre="the PHEIC on 10th of August 2009 Thirty-nine countries reported" exact="treatment" post="data. The highest number of papers was published by"/>
 <result pre="of papers was published by the USA (nâ€‰=â€‰25, reporting 2559" exact="treatment" post="courses), followed by China (nâ€‰=â€‰16, reporting 14,680 treatment courses)"/>
 <result pre="reporting 2559 treatment courses), followed by China (nâ€‰=â€‰16, reporting 14,680" exact="treatment" post="courses) and Spain (nâ€‰=â€‰16, reporting 4103 treatment courses). Country-level"/>
 <result pre="(nâ€‰=â€‰16, reporting 14,680 treatment courses) and Spain (nâ€‰=â€‰16, reporting 4103" exact="treatment" post="courses). Country-level data describing the number of publications and"/>
 <result pre="treatment courses). Country-level data describing the number of publications and" exact="treatment" post="courses described and the first date of patient enrolment"/>
 <result pre="Twenty-three per cent (36/160) of papers described adverse effects from" exact="treatment" post="had occurred. In 42% of cases, adverse effects or"/>
 <result pre="comprising 10 interventional trials and 5 observational studies (2 with" exact="treatment" post="efficacy outcomes, and 3 with general acute clinical outcomes)"/>
 <result pre="these assumed insufficiencies. This paper demonstrates that despite over 33,000" exact="treatment" post="courses being described for hospitalised patients with influenza A(H1N1)pdm09"/>
 <result pre="with influenza A(H1N1)pdm09 during the pandemic, fewer than 600 received" exact="treatment" post="(or placebo) as participants in a registered interventional clinical"/>
 <result pre="the COVID-19 pandemic. Several drugs are being investigated as potential" exact="treatment" post="for COVID-19, but we note that some early published"/>
 <result pre="inform future clinical care. We found that most descriptions of" exact="treatment" post="courses were in retrospective observational studies or case series,"/>
 <result pre="of an outbreak (as was observed here) but also by" exact="testing" post="trial design and establishing research capacity. Novel trial designs,"/>
 <result pre="the EVD outbreak in Liberia that prematurely halted a clinical" exact="treatment" post="trial) [25] or the temporary closure of health care"/>
 <result pre="here, China was heavily represented and reported the majority of" exact="treatment" post="courses described (14,680; 43.3% of the total). Patient characteristics"/>
 <result pre="precision of any estimate is affected by excluding papers where" exact="treatment" post="was not clearly defined and when pandemic strain influenza"/>
 <result pre="for pragmatic reasons. Conclusions Here, we demonstrate how tolerance of" exact="treatment" post="under compassionate care circumstances during the influenza A(H1N1)pdm09 pandemic"/>
 <result pre="not matched with a commitment to capture high-quality data on" exact="treatment" post="use and therefore failed the standards expected of modern"/>
 <result pre="or sleeper protocols as potential solutions to improve accumulation of" exact="treatment" post="data during a pandemic. Supplementary information LINK Additional file"/>
 <result pre="systematic review. Appendix 5. Country level data demonstrating number of" exact="treatment" post="courses described in the literature, and date of first"/>
 <result pre="patients with pneumonia in China, 2019N Engl J Med2020382872773310.1056/NEJMoa200101731978945 2.DobsonJWhitleyRJPocockSMontoASOseltamivir" exact="treatment" post="for influenza in adults: a meta-analysis of randomised controlled"/>
 <result pre="for patients with severe 2009 influenza A(H1N1) infectionChest.2013144246447310.1378/chest.12-290723450336 7.WangCHChungFTLinSMHuangSYChouCLLeeKYet al.Adjuvant" exact="treatment" post="with a mammalian target of rapamycin inhibitor, sirolimus, and"/>
 <result pre="&amp;lt;2 years with influenzaJ Infect Dis2013207570972010.1093/infdis/jis76523230059 10.IsonMGFraizJHellerBJaureguiLMillsGOâ€™RiordanWet al.Intravenous peramivir for" exact="treatment" post="of influenza in hospitalized patientsAntivir Ther201419434936110.3851/IMP268023985625 11.MartyFMManCYvan der HorstCFrancoisBGarotDManezRet"/>
 <result pre="Ther201419434936110.3851/IMP268023985625 11.MartyFMManCYvan der HorstCFrancoisBGarotDManezRet al.Safety and pharmacokinetics of intravenous zanamivir" exact="treatment" post="in hospitalized adults with influenza: an open-label, multicenter, single-arm,"/>
 <result pre="Infect Dis2014209454255010.1093/infdis/jit46723983212 12.LeeNHuiDSZuoZNgaiKLLuiGCWoSKet al.A prospective intervention study on higher-dose oseltamivir" exact="treatment" post="in adults hospitalized with influenza a and B infectionsClin"/>
 <result pre="L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="23.RojekAMDunningJLeliogdowiczACastleLVan LieshoutMCarsonGet al.Regulatory and operational complexities of conducting a clinical" exact="treatment" post="trial during an Ebola virus disease epidemicClin Infect Dis20186691454145710.1093/cid/cix106129206908"/>
 <result pre="2015. Available from: https://acmedsci.ac.uk/file-download/38069-561595082cd83.pdf. Accessed 29 Apr 2020. 25.DunningJKennedySBAntierensAWhiteheadJCigleneckiICarsonGet al.Experimental" exact="treatment" post="of Ebola virus disease with brincidofovirPLoS One2016119e016219910.1371/journal.pone.016219927611077 26.ChengVCChanJFcollab: To"/>
 <result pre="virus disease with brincidofovirPLoS One2016119e016219910.1371/journal.pone.016219927611077 26.ChengVCChanJFcollab: To KKYuenKYClinical management and" exact="infection" post="control of SARS: lessons learnedAntivir Res2013100240741910.1016/j.antiviral.2013.08.01623994190 27.KayemNDRojekADenisESalamAReisAOlliaroPet al.Clinical REsearch"/>
 <result pre="[updated June 29 2020]. Available from: https://rapidreviewscovid19.mitpress.mit.edu/pub/press-release. 38.ZambonMDevelopments in the" exact="treatment" post="of severe influenza: lessons from the pandemic of 2009"/>
</results>
